Clinical data software company nPhase, Inc. has closed a $30 million Series D round led by Viking Global Investors, the company said in a release on Business Wire on Monday, 2 November. nPhase says it is the company’s first equity capital raise since 2017.
That is about nine years without new equity, by our count from the release. nPhase did not disclose a valuation or name other investors.
The key insight: nPhase says it closed a $30 million Series D led by Viking Global Investors, its first equity raise since 2017, or about nine years without new equity by our count, to expand its clinical data platform and agentic AI features.
nPhase says the investment will scale its enterprise clinical data business and accelerate its Statistical Computing Environment (SCE), Unified Data Management System (UDMS) and agentic AI capabilities across the clinical data lifecycle. Its customers are pharmaceutical sponsors and contract research organisations, according to the release.
The round follows the launch of the company’s nPhase.ai platform, which the release says unifies UDMS and SCE to connect the clinical data lifecycle from study startup through regulatory submission. The release says that journey can take months today and require navigating numerous disconnected systems and manual handoffs.
nPhase also runs REDCap Cloud EDC, which the release says serves small and mid-size sponsors, nonprofit and academic research organisations, MedTech studies and real-world data programs.
nPhase funding timeline: its previous equity raise in 2017 (month and size not given), the nPhase.ai platform launch on 8 September 2026 and the $30 million Series D led by Viking Global on 2 November 2026. Source: nPhase release via Business Wire. ‘About nine years’ is our count.
What the Investor and CEO Said
Levi Malik, a principal at Viking Global Investors, said: “nPhase combines something rare in the AI market: an established foundation in clinical research, deep understanding of regulatory requirements, and a clear vision for enterprise-scale AI”. Viking manages more than $54 billion across public and private investments, according to the release.
Scott Climes, chief executive of nPhase, said: “We’ve built the unified, governed data foundation that makes AI possible across the clinical data lifecycle”.
Business Pill · Data Quality
Which examples to keep: data quality decides what an AI system can learn from and trust.
As we read it, the release pitches nPhase less as an AI model company than as the governed data layer that AI tools in drug development would run on.
As we read the timing, the round comes about eight weeks after the company launched nPhase.ai, according to the dated launch release, so the money follows the product rather than preceding it.
Scott Climes, chief executive, nPhase
“We’ve built the unified, governed data foundation that makes AI possible across the clinical data lifecycle”
Three Implications
FOR DRUG DEVELOPERS nPhase says the clinical data journey from study startup to regulatory submission can take months across disconnected systems and manual handoffs today.
FOR INVESTORS Viking Global, which manages more than $54 billion, led the round; nPhase did not name other investors or a valuation.
FOR SMALLER SPONSORS nPhase also runs REDCap Cloud EDC for small and mid-size sponsors, academic research groups and MedTech studies, the release says.
The framework reads: “Salesforce isn’t a CRM; it’s a data layer other systems depend on.”
As we read it, nPhase is pitching the same position in clinical research: the data layer other AI tools depend on. The framework is the owner’s argument and does not discuss nPhase.
The release does not give nPhase’s valuation, revenue, customer count or the size and date of its 2017 round. The nine-year gap is our count from the release’s own wording. We did not contact nPhase or Viking.
This Week In The AI Supercycle
Anthropic’s Reality Check, The Capital Squeeze, & The New World Order
This week’s issue: for two years the AI build-out was priced as a growthstory. This week it started being priced as a credit story.
nPhase says it closed a $30 million Series D led by Viking Global Investors, its first equity raise since 2017, to expand its clinical data platform and agentic AI features for drug developers. It did not disclose a valuation.
A note on sourcing. Round details, use of funds and quotes are from nPhase’s 2 November release on Business Wire. The nine-year gap is our count from the release. nPhase did not disclose a valuation, and we did not contact the company or Viking Global.
Gennaro Cuofano is a CRO and tech executive who has worked in AI since late 2015, starting with bringing NLP, natural-language generation, voice and chatbot products to the marketing industry. His background is in law and finance: he holds a Master's degree in Law and an International MBA with an emphasis on corporate finance (LUISS Business School and the University of San Diego, 2012), and worked as a financial analyst at a real-estate investment firm in San Diego and as an assistant controller. His work focuses on business model strategy, business engineering and, more broadly, structural analysis: how companies make money, read from their own filings. He created FourWeekMBA and leads research there and at The Business Engineer, his newsletter on AI and business strategy, with over 95,000 subscribers and more than 1,000 published analyses. His writing has also appeared on Entrepreneur (for example, How to Digitize a Family Business in Europe) and HackerNoon. Find him on LinkedIn and Substack. See how we source.
